Homocysteine as a marker for predicting disease severity in patients with COVID-19

Biomark Med. 2022 May;16(7):559-568. doi: 10.2217/bmm-2021-0688. Epub 2022 Mar 28.

Abstract

Aim: Our study was designed on the hypothesis that homocysteine levels are a prognostic parameter that can predict the severity of COVID-19 disease. Materials & methods: 117 COVID-19 patients and 34 non COVID-19 individuals were included in the study. Receiver operating characteristic (ROC) analysis was performed for homocysteine, D-dimer and monocyte/lymphocyte ratio (MLR) levels. Results: According to the ROC analysis, in COVID-19 patients group, Area under curve (AUC) values were 0.835 for homocysteine, 0.859 for D-dimer and 0.882 for MLR. According to the ROC analysis, in which homocysteine, MLR and D-dimer parameters were evaluated together, AUC values were 0.951 in the mild disease group, 1000 in severe disease group and 0.967 in COVID-19 patients group. Conclusion: It was concluded that homocysteine level is an important parameter in the follow-up of COVID-19 disease.

Keywords: COVID-19; D-dimer; disease severity; homocysteine; inflammation; monocyte lymphocyte ratio; personalized COVID-19 management; predictive medicine; targeted prevention.

MeSH terms

  • COVID-19* / diagnosis
  • Homocysteine
  • Humans
  • Lymphocytes
  • Prognosis
  • ROC Curve
  • Retrospective Studies
  • Severity of Illness Index

Substances

  • Homocysteine